Clinical Diagnosis and Treatment Analyses on SMARCB1 (Integrase Interactor 1)–Deficient Sinonasal Carcinoma: Case Series with Systematic Review of the Literature
World Neurosurgery, ISSN: 1878-8750, Vol: 161, Page: e229-e243
2022
- 7Citations
- 16Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations7
- Citation Indexes7
- CrossRef3
- Captures16
- Readers16
- 16
Article Description
This study aims to improve the understanding of SMARCB1 (integrase interactor 1)–deficient sinonasal carcinoma (SDSC) by analyzing its clinical features, treatment strategies, and prognosis. Sixty-nine patients were included in this research: 15 new cases from Beijing Tongren Hospital and 54 previously reported cases. We analyzed and summarized patients' epidemiologic data, clinical features, and treatment regimens. Main outcomes were overall survival (OS) and recurrence-free survival (RFS). Univariate and multivariate analyses were performed using a Cox regression model for OS and RFS. SDSC was more common in men than women with a median age of 52 years (range, 21–89 years). Epistaxis (40.0%) and headache (36.7%) were the major symptoms. The most common affected paranasal sinus was the ethmoid sinus (58.0%). For TNM stage, 66.7% cases were first diagnosed as T4N0M0. The tumor cells were complete loss of integrase interactor 1 in all cases by immunohistochemical analysis. However, 72.5% patients were first misdiagnosed initially. The 1-year, 3-year, and 5-year OS and RFS were 85.3%, 51.8%, 47.8%; and 56.8%, 38.2%, and 35.3%, respectively. The RFS of comprehensive treatment based on surgery was better than that of systemic therapy without surgery ( P < 0.05). In addition, the OS and RFS of surgery with chemoradiotherapy was better than that of surgery with radiotherapy ( P < 0.05). Univariate and multivariate analysis identified treatment modality as an independent prognostic factor for patients with SDSC. Immunohistochemical analysis of SDSC during initial biopsy can prevent delays in diagnosis and treatment. Radical surgery resection combined with chemoradiotherapy may be the preferred treatment modality.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1878875022001280; http://dx.doi.org/10.1016/j.wneu.2022.01.114; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85125473644&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35123020; https://linkinghub.elsevier.com/retrieve/pii/S1878875022001280; https://dx.doi.org/10.1016/j.wneu.2022.01.114
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know